Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA)
My previous session
Most popular
  Report  
SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweetsMarketScreener Strategies

Teva Pharmaceutical Industries : FDA Approves Teva's Migraine Drug Ajovy -- Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/15/2018 | 02:21am CET

By Maria Armental

The U.S. Food and Drug Administration has approved for sale Teva Pharmaceutical Industries Ltd.'s (TEVA, TEVA.TV) migraine drug Ajovy, the latest in a new class of drugs that target a brain chemical known as CGRP.

Researchers have found that CGRP, which stands for calcitonin gene-related peptide, is involved in the brain's pain-signaling during migraines.

Ajovy should be available in about two weeks, Teva said, and its wholesale-acquisition cost--an industry term for the price drug companies charge wholesalers--will be about $575 for a 225 mg monthly dose and $1,725 for a 675 mg quarterly dose.

The most common adverse reactions in clinical trials were injection-site reactions, the company said.

Amgen Inc. and Novartis AG's Aimovig, the first of the new type of migraine drugs to hit the U.S. market, was approved in May with a list price of $6,900 a year.

Teva, the world's biggest seller of generic drugs, had been counting on the approval of Ajovy, or fremanezumab, to boost sales.

"The way we recover is Ajovy," Chief Executive Kåre Schultz said last month.

The Israeli drugmaker reported a 14% revenue decline for the first half of the year, which the company has attributed in part to continued pricing pressure in its U.S. generics business and generic competition to multiple-sclerosis drug Copaxone.

Shares, which have outperformed the market with a 21% gain this year, rose 6% to $24.25 in after-hours trading.

Write to Maria Armental at maria.armental@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
11/06Drugmaker Mylan's profit beats; puts no timeline on strategic options
RE
11/01TEVA PHARMACEUTICAL INDUSTRIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCI..
AQ
11/01TEVA PHARMACEUTICAL INDUSTRIES : Israel's Teva swings to loss as restructuring p..
AQ
11/01TEVA PHARMACEUTICAL INDUSTRIES : Israel's Teva gives upbeat outlook as restructu..
AQ
11/01TEVA PHARMACEUTICAL INDUSTRIES : Shares Rise as Investors Greet Progress in Turn..
DJ
11/01TEVA PHARMACEUTICAL INDUSTRIES : 3Q Sales Fell 19%
DJ
11/01TEVA PHARMACEUTICAL INDUSTRIES LTD : Results of Operations and Financial Conditi..
AQ
11/01TEVA PHARMACEUTICAL INDUSTRIES : Reports Third Quarter 2018 Financial Results
BU
10/21TEVA PHARMACEUTICAL INDUSTRIES : and New Jersey Governor Murphy Formalize North ..
BU
10/12MYLAN : Gets Favorable Appeals Court Ruling in Patent Dispute Over Teva's Copaxo..
DJ
More news
News from SeekingAlpha
11/16European advisory group backs Teva's migraine med fremanezumab 
11/15Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q3 2018 Update 
11/15Time To Get Onboard Adamis? 
11/14All Good News For Teva's Biosimilars As Sandoz Drops Out 
11/14Dropbox Is A Buy - Cramer's Lightning Round (11/13/18) 
Financials ($)
Chart TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Duration : Period :
Teva Pharmaceutical Industries Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 26,0 $
Spread / Average Target 17%
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani Executive Vice President-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED22 752
JOHNSON & JOHNSON3.42%391 542
PFIZER19.30%252 358
NOVARTIS6.38%222 056
ROCHE HOLDING LTD.1.54%214 508
MERCK AND COMPANY35.17%197 785